Background {#Sec1}
==========

The global burden of chronic obstructive pulmonary disease (COPD) is high \[[@CR1]\]. Some patients with COPD experience three episodes of acute exacerbation per year on average \[[@CR2]\]. Most acute exacerbation episodes require medical attention, either in primary care or in hospital \[[@CR3]\].

Predictive factors of exacerbation are still not completely understood \[[@CR4]--[@CR9]\]. However, acute exacerbations are known to accelerate the severity of disease, \[[@CR3]\] contribute to irreversible decline of pulmonary function \[[@CR10]\], have a negative impact on quality of life \[[@CR11]\] and decrease survival \[[@CR12]\]. The proportion of treatment failure in patients with acute exacerbations is high (20--40 %) \[[@CR13]\] and it is associated with elevated health costs \[[@CR14]\].

Traditionally, a decrease in forced expiratory volume in one second (FEV~1~) has been considered one of the main risk factors of exacerbation. However, FEV~1~ does not discriminate between stable periods of disease and acute exacerbations, and is less effective in the late stages of the disease \[[@CR3]\]. Indeed, some patients with low FEV~1~ have never experienced acute exacerbations, and a higher FEV~1~ does not rule out the risk of exacerbation \[[@CR15]\].

It is essential to consider COPD as a systemic disease rather than just pulmonary, since it is associated with symptoms in other organs and with comorbidities \[[@CR16], [@CR17]\] that can determine the risk of acute exacerbation. Consequently, new multifactorial predictive models for exacerbation are required \[[@CR18]\]. The BODE index, which comprises Body Mass Index, airflow Obstruction, Dyspnoea and Exercise (distance walked in 6 min) is a predictive factor of mortality in COPD and a better predictive factor for acute exacerbation than FEV~1~ \[[@CR19]\]. The study of Marin et al. showed that the BODE index was a better predictive method than FEV~1~ for acute exacerbation in patients with COPD \[[@CR19]\]. However, the six minute walk test is not easily implemented in primary care. Other models have been proposed \[[@CR20]--[@CR22]\]. Nonetheless, new models with variables that can be obtained easily and quickly are needed.

Factors related to acute exacerbation are still poorly understood \[[@CR5]\]. Some variables have been identified with risk of exacerbation. However, further studies are needed to prove the association of these factors with acute exacerbation and to validate models of prediction \[[@CR23]\].

Factors such as the characteristics of the population, prevalence of risk factors, severity of COPD and aspects of the health system \[[@CR3]\] result in a geographical variation in the incidence of exacerbation \[[@CR24]\]. In consequence, predictive models should be adjusted to different settings.

The objective of this study was to determine predictive factors associated with exacerbation of COPD in a primary care cohort of patients in Catalonia (Spain) with a high percentage of mild and moderate severity during a three year follow up.

Methods {#Sec2}
=======

A retrospective cohort study was carried out with 2501 patients with a COPD diagnosis from seven primary care centres of the Lleida Health Region (catchment population: 172,950). The criteria of inclusion were over 40 years of age with a diagnosis of COPD in 2010 in primary care electronic medical records and having a spirometry test in the last two years*.* GOLD criteria were followed for the diagnosis of COPD: \[[@CR25]\] a post bronchodilator FEV~1~/FVC \<0.7 when the patient is in the stable phase of the disease. For a patient to be included in the study, the electronic medical records must also contain the result of a spirometry test from the previous 2 years. The dependent variable was acute exacerbation of COPD, defined as an increase in dyspnoea, amount and purulence of sputum \[[@CR26]\] that require treatment with systemic steroids and/or antibiotics (moderate exacerbations) or that require hospitalization (severe exacerbations) \[[@CR27]\]. The referral hospitals were the University Hospital Arnau de Vilanova and the Hospital Santa Maria de Lleida. These were the two hospitals where the patients that required admission were referred. Exacerbations between November 2010 and October 2013 were computed. Data sources were the primary care electronic medical records (e-CAP) and the Health Department Pharmacy Unit Register. The following independent variables were collected at the beginning of the study: age, gender, spirometry results (FEV~1~/CVF, FVC, FEV~1~), comorbidities (heart failure, ischemic heart disease, diabetes, chronic kidney failure, atrial fibrillation and anaemia), history of smoking, 23-valent pneumococcal and influenza immunisations for the 2009/10 season, years since COPD was diagnosed, number of visits to the health centre and number of acute exacerbations in the year prior to the start of the study, and COPD severity according to the GOLD Guidelines.

This study was approved by the Clinical Research Ethics Committee of the Primary Care Research Institute (IDIAP) Jordi Gol of Barcelona (P14/022). This ethics committee determined that individual patient consent was not necessary due to the retrospective nature of the study. We also obtained the consent by management of all the seven primary care centres participating in the study (Lleida, Pla d'Urgell, Les Borges Blanques, Bellpuig, Tàrrega, Agramunt and Cervera) as well as the approval by the management of Primary Care of the Healthcare Region of Lleida. The Primary Care Management of the Catalan Institute of Health authorized permission to access the clinical records of the patients included in the study with the ultimate aim of gathering information concerning the variables of interest.

Statistical analysis {#Sec3}
--------------------

A descriptive analysis of the data was performed. Quantitative variables were described using the mean and standard deviation and categorical variables using the absolute and relative frequencies. Hypothesis testing to evaluate the association of independent variables with the clinical outcome (COPD exacerbation) was performed using the Chi-square test for categorical variables and Student's *t* test or Mann-Whitney's *U* test for continuous variables. The crude odds ratio (OR) was calculated for each independent variable included in the model.

A derivation cohort (70 %) and a validation cohort (30 %) were randomly generated. The score was adjusted in the derivation cohort and the predicted probability, power and calibration were estimated from the 30 % included in the validation cohort. The score included all variables associated with an outcome with a *P* value \<0.2. The risk score was adjusted for the 3-year period with a logistic regression analysis using automatic (forward and backward) variable selection algorithms. Selected variables were included in the model if the *P* value of the effect was \<0.1. The characteristics of the calibration were evaluated by the Hosmer-Lemeshow test and the discriminatory power using the *c-* statistic of the area under the curve (AUC).

Statistical Interaction and quadratic effect were tested for all quantitative variables. Statistical significance was considered if *P*-value \<0.05. All analyses were performed using the statistical package SPSS v15.0.

Results {#Sec4}
=======

Mean age of the 2501 patients at the start of the study was 68.38 years (SD = 11.60) and 75 % were men. Severity of disease (GOLD) was mild in 50.82 % patients, moderate in 35.31 %, severe in 9.44 % and very severe in 4.44 %. The year prior to the start of the study a total of 20.23 % patients had experienced at least one episode of acute exacerbation and the average number of visits to the physician or nurse in primary care was 25. With regard to immunisation, 70.45 % had received the 23-valent pneumococcal vaccine and 71.41 % the influenza vaccine during the 2009/10 season (season prior to the start of the study).

Table [1](#Tab1){ref-type="table"} shows the characteristics of the patients in relation to acute exacerbations. Patients who experienced acute exacerbations were older, had attended the primary care centre more often during 2009, presented more comorbidities (heart failure, ischemic heart disease, diabetes, chronic kidney failure, atrial fibrillation and anaemia) and had experienced more acute exacerbations during the year prior to the start of the study. Up to 83.17 % of patients experienced at least one episode of acute exacerbation during the 3-year follow up. Patients with a higher severity of disease (GOLD grades III and IV) experienced higher rates of acute exacerbation (Table [2](#Tab2){ref-type="table"}), and had higher rates of immunisation with the 23-valent pneumococcal and influenza vaccines during the 2009/2010 season (*p* \<0.001).Table 1Characteristics of patients at the beginning of the study and description of variables associated with acute exacerbation during the 3-year follow-upExacerbation (treatment during next 3y)All (*n* = 2501)No (*n* = 421)Yes (*n* = 2080)*p*Age^a^65.62 (11.90)68.94 (11.50)0.00168.38 (11.60)COPD History (years)^a^2.86 (3.50)3.69 (4.40)0.0013.55 (4.30)Num. of visits (2009)^a^18.01 (14.30)25.96 (18.70)0.00124.63 (18.30)FEV166.38 (23.20)62.80 (24.40)0.00463.38 (24.30)Gender (female)^b^79 (18.76 %)547 (26.30 %)0.001626 (25.03 %)23-valent Pneumococcal^b^242 (57.48 %)1520 (73.08 %)0.0011762 (70.45 %)2009 influenza vaccine^b^242 (57.48 %)1544 (74.23 %)0.0011786 (71.41 %)Exacerbation 2009^b^20 (4.75 %)486 (23.37 %)0.001506 (20.23 %)Number of comorbidities^c^0.34 (0.70)0.45 (0.70)0.0020.43 (0.70)Smoking^b^178 (42.28 %)666 (32.02 %)0.001844 (33.75 %)Gold (Severity)^b^0.062Mild COPD223 (52.97 %)1048 (50.38 %)1271 (50.82 %)Moderate COPD157 (37.29 %)726 (34.90 %)883 (35.31 %)Severe COPD27 (6.41 %)209 (10.05 %)236 (9.44 %)Very Severe COPD14 (3.33 %)97 (4.66 %)111 (4.44 %)Hospital Admission^b^62 (14.73 %)750 (36.06 %)0.001812 (32.47 %)Death^b^39 (9.26 %)275 (13.22 %)0,025314 (12.55 %)^a^mean (SD): Mann--Whitney *U* test^b^absolute and relative frequency. Chi-square test^c^Number of comorbidities: Ischemic Heart Disease, Heart Failure, Diabetes, Anaemia, Atrial Fibrillation and Chronic Renal FailureThe statistical significance is fixed for *p*-value \<0.05Table 2Immunisation and acute exacerbation in relation to severity of COPDMildModerateSevereVery SevereAll*p*(*n* = 1271)(*n* = 883)(*n* = 236)(*n* = 111)(*n* = 2501)23-valent Pneumococcal^a^866 (68.14 %)628 (71.12 %)185 (78.39 %)83 (74.77 %)1762 (70.45 %)0.0022009\
influenza vaccine^a^880 (69.24 %)636 (72.03 %)183 (77.54 %)87 (78.38 %)1786 (71.41 %)0.002Exacerbation (treatment during next 3y or hospital admission)^a^1048 (82.45 %)726 (82.22 %)209 (88.56 %)97 (87.39 %)2080 (83.17 %)0.043^a^Absolute and relative frequency. Chi-square test

The multivariate analysis (Table [3](#Tab3){ref-type="table"}) shows that the following factors are significantly associated with COPD exacerbation: age (mean 68 years (~a~OR = 1.01), gender (woman) (~a~OR = 1.46), gender (woman) x age (mean 68 years (~a~OR = 0.96), previous exacerbations (~a~OR = 7.44), severe or very severe disease (GOLD), (~a~OR = 1.57), number of visits to the primary care centre (from 25 to 50 visits (~a~OR = 1.64); over 50 visits (~a~OR = 2.95) in relation to the standard (\<25 visits), influenza vaccine (~a~OR = 2.00), 23-valent pneumococcal vaccine (~a~OR = 1.82), influenza x 23-valent pneumococcal vaccine (~a~OR = 0.46). Patients immunised with the pneumococcal and influenza vaccines had a 54 % lower risk of exacerbation. All these variables were significantly associated with COPD exacerbation, with a discriminatory power of 0.71. Fig. [1](#Fig1){ref-type="fig"} shows the calibration and discriminatory power of the predictive model. The predictive factor more strongly associated with disease exacerbation was acute exacerbation during the year prior to the start of the study, which increased the risk of experiencing acute exacerbation by 7.44 during the following 3 years.Table 3Predictive factors of COPD exacerbation during the 3-year follow-up periodExacerbation (treatment in next 3y)OR95 % CIpNum. Of visits 2009 (Standard \< 25v)0.001 25--501.64(1.17 -- 2.29)0.004 \> 502.95(1.25 -- 6.94)0.013Gender (female)1.46(1.04 -- 2.04)0.028Exacerbation7.44(3.77 -- 14.70)0.001INT: Female \* Age (mean 68y)0.96(0.93 -- 0.99)0.003Age (mean 68y)1.01(1,00 -- 1.03)0.087Gold severity grade (severe or very severe)1.57(1.01 -- 2.45)0.0462009 influenza vaccine2.00(1.12 -- 3.58)0.01923-valent Pneumococcal vaccine1.82(1.00 -- 3.29)0.049INT: 2009 influenza vaccine \* Pneumococcal0.46(0.20 - 1.02)0.055Derivation Hosmer & Lemeshow1.100.997 AUC ROC0.71(0.68 -- 0.74)\< 0.001Validation Hosmer & Lemeshow41.00\<0.001 AUC ROC0.69(0.64 -- 0.74)\<0.001*INT* Interaction*OR* odds ratio*OR was adjusted for: Num. of visits, gender, exacerbation, GOLD severity grade, influenza vaccine, 23-valent pneumococcal vaccine*Fig. 1Exacerbation ROC curve after 3 years of follow up (validation and derivation cohorts)

Discussion {#Sec5}
==========

In this study, patients with at least one episode of exacerbation during the 3-year follow-up were older and more often men; they had a higher COPD severity grade (GOLD III and IV), they had experienced more acute exacerbation episodes during the year prior to the study and had attended the primary care centre more often due to a higher prevalence of comorbidities. Older patients experienced a higher rate of acute exacerbation episodes, probably because pulmonary function decreases with time and because of the accumulative effect of risk factors such as smoking. On the other hand, this study confirms the effectiveness of the influenza and 23-valent pneumococcal vaccines. Indeed, immunisation reduces risk practically by half. This model could be used in primary care visits to identify patients with a higher risk of exacerbation.

Interpretation of results based on the literature {#Sec6}
-------------------------------------------------

Other authors have researched similar predictive models for exacerbation, with slight differences. Miravitlles et al. \[[@CR28]\] designed a model for exacerbation with the following variables: age, FEV~1~ (GOLD severity) and chronic sputum production, and obtained an area under the ROC curve (AUROC) of 0.601 . Our model also includes age and FEV~1~, though it achieves a higher discriminatory power. Motegi et al. \[[@CR29]\] compared three predictive models of COPD exacerbation: the DOSE (dyspnoea, degree of airflow limitation, smoking and exacerbations); BODE (body mass index, degree of airflow limitation, dyspnoea and exacerbations); and ADO (age, dyspnoea, degree of airflow limitation) indices. These predictive models had a discriminatory power (ROC curve) of 0.75, 0.65 and 0.64, respectively. The authors concluded that the best model to predict future exacerbations in COPD patients was the DOSE index. Our model has a higher AUROC than those found by Motegi et al. for the BODE and ADO indices, and it also contains risk factors common to the three models: age, degree of airflow limitation and history of exacerbation. Make et al. \[[@CR20]\] developed a score (SCOPEX) that included variables such as gender, number of COPD maintenance medications, number of exacerbations in the previous year, FEV1/FVC and number of daily short-acting bronchodilators for clinicians to predict exacerbations. Moberg et al. \[[@CR21]\] used measures of exercise capacity and dyspnoea scores to develop the iBODE index as a predictor. While Schembri et al. \[[@CR22]\] also developed a predictive model based on data collected from clinic visits on demography, spirometry, smoking history, dyspnoea score, BMI and other variables.

In our model, a history of exacerbation is the best predictive factor for exacerbation, followed by an age over 68. The study by Hurst et al. also concluded that a history of exacerbation during the previous year was the best predictive factor of acute exacerbation \[[@CR27]\].

As in other studies, the male sex was a risk factor of exacerbation due to the smoking habits. However, other studies have reported a higher risk of exacerbation in females \[[@CR30]\].

Our study further supports the evidence on the effectiveness of influenza and 23-valent pneumococcal immunisations in significantly reducing the risk of acute exacerbation \[[@CR31], [@CR32]\]. This study contributes a new predictive model of COPD exacerbation with variables that are easily and swiftly collected. The high discriminatory power makes this model adequate for use in primary care.

Strengths and limitations of the study {#Sec7}
--------------------------------------

The main strengths of the study are the length of the follow-up period (3 years) and characteristics of the cohort (the sample consists of a high percentage of patients with mild and moderate severity, unlike other studies, thus, our sample is more representative of the spectrum of the disease in the community. The primary care electronic medical records include all patients with a diagnosis of COPD in our region. In contrast, hospitals registers only include patients with the most severe forms of the disease. The study has also some limitations. The information was obtained from primary care electronic medical records, where some variables such as smoking and influenza and pneumococcal immunisations can be underreported. Some series like the UPLIFT studies found a prevalence of 29 % of smokers, \[[@CR33]\] whereas another reports a prevalence as low as 4.4 % \[[@CR6]\], much less than our study.

The study included patients with a diagnosis of COPD and with a spirometry result from 2 years prior to the start of the study. These inclusion criteria ensure that all patients were correctly diagnosed, but might exclude patients with COPD either because of underreporting or because they did not have a spirometry result in their electronic medical records. Such patients would probably be those with a mild disease. Also, patients were considered immunised against influenza or pneumococcal disease only when the immunisation was registered in the eCAP. When patients are immunised in private clinics it might not be adequately recorded. Some patients may give up smoking after the study and this change was not registered. Consequently, the effects of smoking and the protective effect of immunization might be underestimated. With regard to influenza immunisation, we only considered the 2009/10 seasonal immunisation. However, immunised patients tend to attend immunisations every year \[[@CR34]\] and thus those immunised during the 2009/10 season were probably also immunised during the following seasons. Some variables studied in other models, such as weight/BMI, exercise/functional capacity or dyspnoea, were not investigated due to a lack of comprehensive information for all patients. Lastly, we must highlight that the predictors objectified in this study may vary depending on the geographical area of the study and the characteristics of health systems specific for each one, which is why more studies are needed in different health regions.

Implications for future research and practice {#Sec8}
---------------------------------------------

Some risk factors might vary in different settings. Other variables should be investigated in other future models and in other places, like the number of medication \[[@CR20]\], seasonality \[[@CR35], [@CR36]\], sleep disturbance\[[@CR37]\] and exposure to pollutants \[[@CR38], [@CR39]\]. Our study reports risk factors of COPD exacerbation in a specific region of Spain. External validation of this predictive model is required before implementing it in other cohorts of patients with COPD.

Conclusions {#Sec9}
===========

This predictive model of acute exacerbation in COPD can be easily and quickly implemented in primary care. Patients at high risk could be identified for preventive action, such as immunisation and for intensification of treatment. As a consequence, quality of life and survival rates in patients with COPD would improve.
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